Efforts to expand 340B protections often bring questions about oversight, cost, and the intended use of program savings to the foreground.
The case for expansion
Supporters view stronger state protections as a way to preserve discounted-drug access and the community services supported by 340B savings.
Accountability remains central
Clear reporting and measurable patient impact can help covered entities address concerns while demonstrating responsible program stewardship.